Microba Life Sciences Limited (MAP) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone. Very pleased to share an update of our progress following close of the quarter ended 30 June 2024. Joining me on this call is our Head of Therapeutics, Trent Munro. Just moving past our standard disclaimer, Microva is a medical diagnostic and clinical stage therapeutics company, unlocking the medical application of the microbiome, which is the trillions of organisms that live in and on our body, which are critical to our health and development of disease, founded on world-leading metagenomic microbiome analysis technology with a clear vision that that technology would lead to new diagnostic testing solutions that become a routine part of healthcare and lead us to the discovery and development of novel drugs for major chronic diseases. We've invested over the last six years to get there, leveraging high-quality data, and initial revenues generated from the sale and delivery of over 50,000 non-diagnostic personal microbiome tests and the delivery of contract research services from companies and research institutes across the globe wanting to access our technology. From that work, we've amassed what we believe is one of the largest and most valuable microbiome data sets in the world. And that data set has enabled us to execute on the founding vision to unlock those diagnostic and therapeutic opportunities. Now, after many years of development, we've recently launched two diagnostic testing products, MetaPanel for diagnosing gastrointestinal pathogens, launched just a few months ago with Sonic Healthcare, and MetaExplore for diagnosing gastrointestinal disorders, launched just last year. In parallel from interrogating that dataset, We've invested in three therapeutic programs spanning inflammatory bowel disease, immuno-oncology and autoimmune dise...